Cambridge Antibody Technology (CAT) and The Debiopharm Group will develop and commercialize Debiopharm’s fully human monoclonal IgM antibody SC-1 and all derivative products thus generated, according to an exclusive worldwide licensing agreement between the two companies. SC-1 targets CD55SC-1, a cell surface receptor that is specifically expressed on gastric carcinoma cells.
“CAT’s expertise in the development of monoclonal antibodies gives us confidence for the future of SC-1 as a potential treatment for gastric cancer,” comments Loic Maurel, CEO of The Debiopharm Group’s Canadian subsidiary. “As most patients diagnosed with stomach cancer fail to be cured by gastric resection and most trials of pre- or post-surgery chemotherapy show no improvement in survival rates, there is a definite need for better treatment options.”
Under the terms of the agreement, Debiopharm will receive upfront and milestone payments from CAT and royalties on potential future sales.